Iron Use in Patients with Pulmonary Hypertension: A Rapid Systematic Review
https://doi.org/10.20514/2226-6704-2025-15-2-85-101
Abstract
Iron deficiency is widespread in patients with cardiovascular disease. In recent years, the correction of iron deficiency in patients with chronic heart failure has been actively studied to improve the prognosis and course of the disease. Currently, there are not many studies on the use of iron preparations in patients with pulmonary hypertension. The aim of our review was to explore the possibility of using parenteral iron preparations in patients with pulmonary arterial hypertension to improve symptoms and prognosis. The final analysis included 5 publications. According to the results of the presented studies, after the use of iron preparations, laboratory data characterizing iron deficiency were normalized in all patients, exercise tolerance increased, and the quality of life improved. At the same time, according to the indicators of instrumental studies, the parameters were without dynamics, catheterization of the right heart also showed no effect on hemodynamic criteria. In all studies, iron preparations were well tolerated, no serious side effects were detected, which confirms the possibility of widespread use of drugs of this group. Timely diagnosis and treatment of anemia and latent iron deficiency in patients with pulmonary hypertension prevent disease progression. However, at present, in real clinical practice, parenteral iron preparations are rarely used in patients with latent iron deficiency, as a result of which active outreach among practitioners is necessary in order to expand the use of this type of treatment.
About the Authors
K. V. Balkina
V.P. Polyakov Samara Regional Clinical Cardiology Dispensary
Russian Federation
Competing Interests:
Russian Federation
Ksenia V. Bal’kina — cardiologist, State Budgetary Healthcare Institution Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov; Graduate Student of the Departm ent of Propaedeutic Therapy with a Course in Cardiology, Samara State Medical University, Ministry of Healthcare of the Russian Federation
Samara
Competing Interests:
The authors declare no conflict of interests
T. V. Pavlova
V.P. Polyakov Samara Regional Clinical Cardiology Dispensary; Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Tatyana V. Pavlova — MD, PhD, Head of the Clinical Research Department, Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov; Professor of the Department of Propaedeutic Therapy with a Course in Cardiology, Samara State Medical University, Ministry of Healthcare of the Russian Federation
Samara
Competing Interests:
The authors declare no conflict of interests
D. V. Duplyakov
V.P. Polyakov Samara Regional Clinical Cardiology Dispensary; Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Dmitry V. Duplyakov — MD, PhD, Professor, Head of the Department of Propaedeutic Therapy with a Course in Cardiology, Samara State Medical University of the Ministry of Health of the Russian Federation; Deputy Chief Physician for Medical Affairs, Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov
Samara
Competing Interests:
The authors declare no conflict of interests
References
1. Humbert M., Kovacs G., Hoeper M.M, et al. ESC/ERS Scientific Document Group. 4360 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation ( ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022; 43(38): 3618–3731. http://dx.doi.org/10.1093/eurheartj/ehac237
2. Simonneau G., Montani D., Celermajer D.S., et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53:1801913. https://doi.org/10.1183/13993003.01913-2018
3. Chazova I.E., Martynyuk T.V., Shmalts A.A., et al. Eurasian recommendations for the diagnosis and trea tment of pulmonary hypertension (2023). 2024;(1):6-85. DOI: 10.38109/2225-1685-2024-1-6-85 (in Russian).
4. Hoeper M.M., Humbert M., Souza R. et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306-22. doi: 10.1016/S2213-2600(15)00543-3.
5. Anker S.D., Comin Colet J., Filippatos G. et al.; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. doi: 10.1056/NEJMoa0908355.
6. van Veldhuisen, D.J., Ponikowski, P., van der Meer, P.et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency. Circulation, 2017,136, 1374-1383. doi: 10.1161/CIRCULATIONAHA.117.027
7. Sonnweber T., Nairz M., Theurl I. et al. The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension. PLoS ONE, 2018, 13(8): e0203396. doi: 10.1371/journal.pone.0203396
8. Rhodes C.J., Howard L.S., Busbridge M. et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58(3):300-9. doi: 10.1016/j.jacc.2011.02.057.
9. Rhodes C.J., Wharton J., Ghataorhe P. et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med. 2017;5(9):717-726. doi: 10.1016/S2213-2600(17)30161-3.
10. Van Empel V.P., Lee J., Williams T.J., et al. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2014;23(3):287-92. doi: 10.1016/j.hlc.2013.08.007.
11. Willie C.K., Patrician A., Hoiland R.L., et al. Influence of iron manipulation on hypoxic pulmonary vasoconstriction and pulmonary reactivity during ascent and acclimatization to 5050 m. J Physiol. 2021;599(5):1685-1708. doi: 10.1113/JP281114.
12. Smith T.G., Balanos G.M., Croft Q.P. et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008;586(24):5999-6005. doi: 10.1113/jphysiol.2008.160960.
13. Cotroneo E., Ashek A., Wang L. et al. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Circ Res. (2015) 116:1680–90. 10.1161/CIRCRESAHA.116.305265
14. Lakhal-Littleton S., Crosby A., Frise M.C., et al. Intracellular iron deficiency in pulmonary arterial smooth muscle cells induces pulmonary arterial hypertension in mice. Proc Natl Acad Sci USA 2019; 116: 13122–13130. doi: 10.1073/pnas.1822010116.
15. Soon E., Treacy C.M., Toshner M.R., et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011; 66: 326–332. DOI: 10.1136/thx.2010.147272
16. Rhodes C.J., Wharton J., Howard L., et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011;38(6):1453-60. doi: 10.1183/09031936.00037711.
17. Viethen T., Gerhardt F., Dumitrescu D., et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. (2014) 175:233–9. doi: 10.1016/j.ijcard.2014.04.233.
18. Ruiter G., Manders E., Happé C.M., et al. Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. Pulm Circ.2015; 5:466–72. 10.1086/682217
19. Blanche C., Alonso-Gonzalez R., Uribarri A., et al. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol . 2018; 267: 79-83. doi: 10.1016/j.ijcard.2018.05.062.
20. Howard LSGE, He Jianguo, Geoffrey M.J. et al. Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials Ann Am Thorac Soc. 2021; 18(6): 981–988. doi: 10.1513/AnnalsATS.202009-1131OC
21. Kramer T., Wissmüller M., Natsina K.et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study, Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1501–1512, 10.1002/jcsm.12764.
22. Tereshchenko S.N. Galyavich A.S., Uskach T.M. et al. Chronic heart failure. Clinical recommendations 2020. Russian cardiol. J 2020; 25(11):311-74. DOI: 10.15829/1560-4071-2020-4083 (in Russian).
23. Ponikowski P., Kirwan B.A., Anker S.D., et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, con- trolled trial. Lancet (London, England). 2020;396(10266):1895–904. DOI: 10.1016/S0140-6736(20)32339-4
24. Mareev Yu.V., Gilyarevsky S.R., Begrambekova Yu.L. et al. The agreed opinion of experts on the treatment of iron deficiency in stable and de compensated patients with chronic heart failure. Cardiology 2021; 61(4): 73–8. DOI: 10.18087/cardio.2021.4.n1639 [in Russian].
25. Zhilenkova Yu.I., Zolotova E.A., Vasilyeva E.Yu. et al. Study of iron me tabolism in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Clin. Lab. diagnostics. 2024; 69(6): 30-43. [in Russian]. DOI: 10.17816/cld629834
26. Avdeev S.N., Barbarash O.L., Valieva Z.S. et al. 2024 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024; 29(11): 6161. [in Russian]. doi: 10.15829/1560-4071-2024-6161. EDN MYEOVA
27. Broberg C.S., Jayaweera A.R., Diller G.P. et al. Seeking the Optimal Relation between Oxygen Saturation and Hemoglobin Concentration in Adults with Cyanosis from Congenital Heart Disease. Am J Cardiol. 2011; 107: 595-9
Review
For citations:
Balkina K.V., Pavlova T.V., Duplyakov D.V. Iron Use in Patients with Pulmonary Hypertension: A Rapid Systematic Review. The Russian Archives of Internal Medicine. 2025;15(2):85-101. https://doi.org/10.20514/2226-6704-2025-15-2-85-101
Views:
302
Email this article 